Global Drugs For Hormonal Replacement Therapy Market (2021 to 2030) - Players Include Novartis, Bayer and Pfizer Among Others
11 nov. 2021 06h43 HE
|
Research and Markets
Dublin, Nov. 11, 2021 (GLOBE NEWSWIRE) -- The "Drugs For Hormonal Replacement Therapy Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to...
Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
26 oct. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA
14 oct. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
22 sept. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing...
Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies
09 sept. 2021 12h46 HE
|
Clarus Therapeutics, Inc.; Blue Water Acquisition Corp.
Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed Clarus Therapeutics Holdings, Inc. Clarus...
Testosterone Replacement Therapy Market Report 2021-2031: Visiongain Research Inc.
03 août 2021 11h29 HE
|
Visiongain Ltd
Visiongain has published a new report on Testosterone Replacement Therapy Market Report 2021-2031: Forecasts By Product (Oral, Parenteral, Implants, Gel/Creams, Patches, Buccal Adhesive, and Others),...
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
15 juil. 2021 09h00 HE
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine...
Clarus Announces JATENZO® (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts
07 déc. 2020 09h00 HE
|
Clarus Therapeutics, Inc.
JATENZO is the first and only FDA-approved oral testosterone replacement therapy of its kind Coverage effective December 1, 2020 on the Express Scripts National Preferred, Basic and High Performance...
CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO® (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM
16 mars 2020 08h00 HE
|
Clarus Therapeutics, Inc.
Financing to speed commercialization of the only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., March 16, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics,...
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism
10 févr. 2020 08h00 HE
|
Clarus Therapeutics, Inc.
First and only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO®...